AR-1105

AR-1105 is a novel, fully biodegradable, sustained-release intravitreal implant designed to deliver dexamethasone over a period of up to six months. The drug utilizes PRINT (Particle Replication In Non-Wetting Templates) technology for controlled release and is administered via intravitreal injection using a small-gauge needle. Its primary mechanism is as a glucocorticoid receptor agonist, providing anti-inflammatory effects in the eye. Developed initially by Aerie Pharmaceuticals and later by Alcon, AR-1105 targets macular edema secondary to retinal vein occlusion (RVO), including both branch and central types. Phase 2 clinical trials have shown that both tested formulations of the implant were well-tolerated and provided clinically meaningful improvements in visual acuity and reductions in retinal thickening for up to six months post-injection[1][2][3][4][7]. The CF2 formulation demonstrated particularly durable efficacy[7]. No patients required surgery or laser intervention for intraocular pressure control during studies.

Other names

Dexamethasone releasing implant - AlconDexamethasone steroid implant - Alcon